Our results delineate the unique role of the PP2A inhibitor proteins in tumorigenesis, and potentially explain why SET and CIP2A are frequently overexpressed concomitantly with mutations in ERK-activating oncogenes in human cancers. This evidence concerns the gene PTPA and cancer.